EGFR and head and neck squamous cell carcinoma: Cetuximab (CTX), a monoclonal antibody targeting the EGFR extracellular domain, is to date the only targeted therapy that has demonstrated benefits in OS in combination with both radiotherapy for patients with locally advanced HNSCC (66) and chemotherapy (platinum, 5-FU, and CTX) as the first-line treatment of patients with recurrent and/or metastatic HNSCC (5, 67).